Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Plan stifles drug innovation – could lose half of all new medicines and treatments. The effect on start ups and small firms is especially pronounced.

Standish Fleming Aug. 4, 2022 The outsized effect of ‘modest’ price controls on pharmaceutical innovation https://www.statnews.com/2022/08/04/outsized-effect-modest-price-controls-pharma-innovation/

Drug price controls in the U.S. Senate are being met with dire warnings that such an approach will stifle innovation, shut off the pipeline of new medicines, and cost lives down the road. Is innovation so fragile that a modest reduction in profits of global giants could seriously impact the supply of new drugs? Small companies originate of all new medicines. Yet the high-cost drugs that lawmakers would target are sold by global giants. Many of them make so much money that they return “excess” profits to shareholders through share buybacks. Congress believes that they can take a portion of those excess profits to balance the federal budget or fight global warming with little risk to productivity. The industry replies that eliminating ”excessive” returns with price controls would remove the financial foundation of the innovation ecosystem. When a company — large or small — considers developing a new treatment, it estimates future returns based on the drug’s ability to lower the cost of caring for patients. Alzheimer’s disease, for example, costs the U.S. per year, which is expected to increase to . Companies developing a drug to treat Alzheimer’s weigh the expected payoff against and an investment of between $1 billion and $3 billion over 10-plus years. Despite those odds, there are in clinical trials for Alzheimer’s disease. What would an effective treatment for Alzheimer’s be worth? Even at $50 billion — a net savings of more than $300 billion per year — it would be a good deal for the country. But would it be feasible with price controls? Humira, the highest grossing medication today, excluding Pfizer’s Covid-19 vaccine. Would the government allow an Alzheimer’s drug to generate more than twice those returns? If Washington, rather than the market, sets the price of drugs, the question of value becomes secondary to political expediency. Companies and investors considering a new drug would not likely risk Alzheimer’s odds knowing that Washington would set a “fair” price for the drug. “Excessive” returns are the business rationale for developing an Alzheimer’s drug. When Gilead introduced the first highly effective drugs to treat hepatitis C, the they generated in one year so threatened budgets that Medicare and Medicaid restricted patients’ access to them. Price controls would have provided a simple solution to the $1,000-per-pill cost of these drugs, but no incentive to develop them in the first place. Experts offer conflicting assessments of the expected drop in the number of drugs produced under with the proposed legislation. My own order-of-magnitude calculation indicates that the projected reduction in the federal deficit — the savings from price controls — of over the next decade could fund the development of 100 to 250 drugs. Researchers with the USC-Brookings Schaeffer Initiative for Health Policy estimated that the industry would lose 10 drugs over 30 years and of undeveloped drugs as likely to “have little impact on the future health of Americans.” A University of Chicago team put the number of lost drugs at and, speaking about cancer (which represents half of total clinical research), concluded that the proposed legislation “will greatly reduce the large activity already taking place in the most active drug class. In turn, this will raise cancer mortality.” The Congressional Budget Office (CBO) appeared to agree with both groups. In January 2022 it forecast a of the expected 1,300 total output of new drugs over the next 30 years. In July, the CBO suggested the loss would be just , then later to . The Brookings, Chicago, and CBO analyses all concluded that the potential loss of new medicines from price controls would be proportional to the loss of revenue, consistent with . The Chicago group forecast an of industry revenue. Would developers of Alzheimer’s drugs similarly trim the pipeline by 26 drugs or, with no way to estimate controlled prices in the future, would they simply walk away? The problem with the “experts’” forecasts is that they are not experts in innovation. Their data showing how pharma has to changes in revenue is dominated by returns to the largest companies, which can make proportional changes to their budgets. But small firms drive the most exciting and potentially valuable drug discovery. Early-stage biotech companies are not miniature versions of multinationals. They serve a specific purpose — innovation — and operate very differently than their larger counterparts.

Reforming the health care system will collapse innovation

Carroll and Frakt 17 [Aaron E. Carroll and Austin Frakt, Aaron E. Carroll is is the chief health officer for and a distinguished professor of pediatrics at Indiana University. Austin Frakt is director of the Partnered Evidence-Based Policy Resource Center at the V.A. Boston Healthcare System; associate professor with Boston University’s School of Public Health; and a senior research scientist with the Harvard T.H. Chan School of Public Health, “Can the U.S. repair its health care while keeping its innovation edge”, published Oct. 9 2017, , accessed 6/26/23] //hacchs

First, let’s acknowledge that the United States is home to an outsize share of global innovation within the health care sector and more broadly. It has more clinical trials than any other country. It has the most Nobel laureates in physiology or medicine. It has won more patents. At least one publication ranks it No. 1 in overall scientific innovation. Strong promotion of innovation in health care is one reason the United States got as far as it did in our recent bracket tournament on the best health system in the world. Though the United States lost to France, 3-2, in the semifinals, it picked up its two votes in part because of its influence on innovation, which can save lives in the United States and throughout the world. Now we shouldn’t delude ourselves into thinking Americans are inherently more innovative than people in other countries. In fact, many American innovators are immigrants who may or may not be citizens. Many technological and procedural breakthroughs in medicine have occurred in other countries. Rather, the nation’s innovation advantage arises from a first-class research university system, along with robust intellectual property laws and significant public and private investment in research and development. Perhaps most important, this country offers a large market in which patients, organizations and government spend a lot on health and companies are able to profit greatly from health care innovation. The United States health care market, through which over one-sixth of the economy flows, offers investors substantial opportunities. Rational investors will invest in an area if it is more profitable than the next best opportunity. “The relationship between profits and innovation is clearest in the biopharmaceutical and medical device sectors,” said Craig Garthwaite, a health economist with Northwestern University’s Kellogg School of Management, and one of the judges in our tournament. “In these sectors, firms are able to patent innovations, and we have a good sense of how additional research funds lead to new products.” High brand-name drug prices, along with generous drug coverage for much of the population, fuel an expectation that large biopharmaceutical research and development investments will pay off. Were American drug prices to fall, or coverage of prescription drugs to retrench, the drug market would shrink and some of those investments would not be made. That’s a potential innovation loss. This is not mere theory, economists have shown. Daron Acemoglu and Joshua Linn found that as the potential market for a type of drug grows, so do the number of new drugs entering that market. Amy Finkelstein showed that policies that made the market for vaccines more favorable in the late 1980s encouraged 2.5 times more new vaccine clinical trials per year for each affected disease. And Meg Blume-Kohout and Neeraj Sood found that Medicare’s introduction of a drug benefit in 2006 was associated with increases in preclinical testing and clinical trials for drug classes most likely affected by the policy. Health care innovation can have direct benefits for health, well-being and longevity. A study led by a Harvard economist, David Cutler, showed that life expectancy grew by almost seven years in the second half of the 20th century at a cost of only about $20,000 per year of life gained. The vast majority of gains were because of innovations in the care for high-risk, premature infants and for cardiovascular disease. These technologies are expensive, but other innovation can be cost-reducing. For instance, in the mid-1970s, new dialysis equipment halved treatment time, saving labor costs.

Sign in to recut, update, or save this card.